Belarus to collaborate with GenoMed on West Nile virus encephalitis

GenoMed, Inc. has announced that the leading experts in West Nile virus encephalitis in Belarus will collaborate with the Company in treating cases of suspected West Nile virus encephalitis this summer. Belarus, formerly part of the USSR, is now a country of 10.5 million people lying between Poland and Russia; its capital is Minsk.

Researchers from the Research Institute for Epidemiology & Microbiology (RIEM) in Minsk, Belarus, consisting of Dr. Tamara Samoilova, Head of the Lab of Arboviral Infections, Professor of Immunology Leonid Titov, Director of the RIEM, and Professor of Neurology Joseph Protas, Head of the Lab of Viral Neuroinfections will test GenoMed's protocol for viral encephalitis in Belarus this summer. Normally, there are 50,000 patients with fever every year in Belarus, including 300 cases of viral encephalitis of uncertain cause. Dr. Samoilova has shown that West Nile virus accounts for a significant fraction of the patients with fever and previously undiagnosed viral encephalitis.

The protocol developed by GenoMed uses drugs currently in use by primary care physicians in every country, available in every drug store, and already proven to be safe. The Belarusian experts share GenoMed's belief that encephalitis and death result from an over-response by a person's immune system to the West Nile virus. GenoMed's protocol, which is patent-pending, gently suppresses the immune system, thus potentially saving the patient from paralysis or death.

GenoMed's treatment has a 100% cure rate so far for immunocompetent patients, including the elderly. No human vaccine yet exists for West Nile virus. No other treatment is as inexpensive, as safe, nor already universally available like GenoMed's.

GenoMed is conducting a free clinical trial for West Nile virus this summer in the United States as well as Belarus, and hopes also to recruit patients from Canada, Israel, Europe, and the Middle East. Patients can enroll by clicking on the "West Nile Trial" button at http://www.genomedics.com.

Dr. Moskowitz, GenoMed's CEO and Chief Medical Officer, is a Harvard- and Oxford-educated physician, who trained for seven years in Internal Medicine, Biochemistry, and Nephrology at Washington University School of Medicine in St. Louis before spending 11 years on the faculty of St. Louis University School of Medicine. He is a noted pioneer in the field of medical genomics, and has been recognized for his groundbreaking treatment of diseases associated with the angiotensin I-converting enzyme, such as chronic renal failure due to hypertension or type II diabetes. Dr. Moskowitz’s novel approach to viral disease, including West Nile virus encephalitis, avian influenza (bird flu), and SARS, are regarded as innovative and potentially useful treatments for currently incurable diseases.